GewissC, AugustinM. Recent insights into comorbidities in atopic Dermatitis®. Expert Rev Clin Immunol, 2023; 19(4):393–404. doi: 10.1080/1744666X.2023.2181790
3.
AielliL, SerraF, CostantiniE, et al.Multiple sclerosis and allergic diseases: is there a relationship?. Allergy, 2022; 6(3):126–152. doi: 10.3934/Allergy.2022011
4.
Oreja-GuevaraC, Ramos-CejudoJ, AroeiraLS, et al.TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab. BMC Neurol, 2012; 12(1):95. doi: 10.1186/1471-2377-12-95
5.
VivekanandanG, AbubackerAP, MyneniR, et al.Risk of progressive multifocal leukoencephalopathy in multiple sclerosis patient treated with natalizumab: A systematic review. Cureus, 13(4):e14764. doi: 10.7759/cureus.14764
6.
BloomgrenG, RichmanS, HotermansC, et al.Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med, 2012; 366(20):1870–1880. doi: 10.1056/NEJMoa1107829
7.
SimopoulouT, TsimourtouV, KatsiariC, et al.Progressive multifocal leukoencephalopathy in a patient with systemic sclerosis treated with methotrexate: a case report and literature review. J Scleroderma Relat Disord, 2020; 5(3):NP1–NP6. doi: 10.1177/2397198320926883
8.
BridgewoodC, WittmannM, MacleodT, et al.T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol, 2022; 142(10):2660–2667. doi: 10.1016/j.jid.2022.03.013
9.
RussoF, ProvvidenzialeL, BruzzichesF, et al.Psoriasis-like eruption triggered by dupilumab therapy. Dermatitis®, 2021; 32(6):e147–e148. doi: 10.1097/DER.0000000000000740
